Skip to content

News & calendar

news: as of 2026-10-09
What the marks mean

Importance is a model-assigned 1–5 on published stories, not a market forecast.

Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.

An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.

Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.

Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.

A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.

Ahead

scheduled · today and tomorrow · calendar refreshed 2026-10-12

Mon · 12 Oct · today

Tue · 13 Oct

Behind

published · newest first

Tue · 14 Jul

product

15:44
Google News: Eisai

Eisai, Biogen report real-world Alzheimer's drug study results

Eisai and Biogen reported real-world study results for their Alzheimer's drug.

Markets open original ↗

product

15:34
Google News: Biogen Inc.

Eisai, Biogen report real-world Alzheimer's drug study results

Eisai and Biogen reported new real-world study results for their Alzheimer's drug.

Markets open original ↗

product

15:12
Google News: Novo Nordisk

Novo Nordisk (CPSE:NOVO B) Reports Fresh Hemophilia Trial Wins In Adults And Children

Novo Nordisk reported positive new hemophilia trial results in both adults and children.

Markets open original ↗

funding

15:00
Google News: VERBUND

Gridcog Secures $10M Funding From ABB, Axpo, DNV and VERBUN

VERBUND joined ABB, Axpo, and DNV as a strategic investor in Gridcog's $10 million funding round.

Markets open original ↗

product

14:44
Google News: Biogen Inc.

Biogen Shares Fall as Alzheimer's Tau Trial Data Disappoint

Biogen shares fell after disappointing trial data for its tau-targeting Alzheimer's drug.

Markets open original ↗

The wire

everything that arrived · 7 days